Effectiveness and safety of first-line atezolizumab in locally advanced or metastatic urothelial cancer: The IMFLAME study. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers ...
FIERCE-HN: A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of ficlatuzumab (HGF/cMET mAb) in combination with cetuximab in participants with recurrent or metastatic (R/M) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results